[
    [
        {
            "time": "",
            "original_text": "华东医药与子公司纠纷最新进展 关联方问题",
            "features": {
                "keywords": [
                    "华东医药",
                    "子公司",
                    "纠纷",
                    "关联方"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药与子公司纠纷最新进展 关联方问题",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：控股子公司珲达生物与多家国内外知名医药企业建立业务关系，其中海外业务占比超过90%，在手长期合作订单较多",
            "features": {
                "keywords": [
                    "华东医药",
                    "珲达生物",
                    "海外业务",
                    "长期合作订单"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：控股子公司珲达生物与多家国内外知名医药企业建立业务关系，其中海外业务占比超过90%，在手长期合作订单较多",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司目前在售主要制剂产品的原料药发酵冬虫夏草菌粉、阿卡波糖等均能自主生产且主要为自用，小部分原料药对外销售，其中又以国际销售为主，国内销售比例较低",
            "features": {
                "keywords": [
                    "华东医药",
                    "原料药",
                    "自主生产",
                    "国际销售"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：公司目前在售主要制剂产品的原料药发酵冬虫夏草菌粉、阿卡波糖等均能自主生产且主要为自用，小部分原料药对外销售，其中又以国际销售为主，国内销售比例较低",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司目前暂无在国内新建Ellansé®伊妍仕®生产线的计划",
            "features": {
                "keywords": [
                    "华东医药",
                    "Ellansé®伊妍仕®",
                    "生产线",
                    "计划"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药：公司目前暂无在国内新建Ellansé®伊妍仕®生产线的计划",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药：OP-101正在美国进行临床Ⅱ期试验 尚未在中国提交相关注册申请",
            "features": {
                "keywords": [
                    "华东医药",
                    "OP-101",
                    "临床Ⅱ期试验",
                    "注册申请"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：OP-101正在美国进行临床Ⅱ期试验 尚未在中国提交相关注册申请",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：OP-101是公司参股公司美国Ashvattha Therapeutics, Inc.的在研产品，目前正在进行临床Ⅱ期试验",
            "features": {
                "keywords": [
                    "华东医药",
                    "OP-101",
                    "Ashvattha Therapeutics",
                    "临床Ⅱ期试验"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：OP-101是公司参股公司美国Ashvattha Therapeutics, Inc.的在研产品，目前正在进行临床Ⅱ期试验",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]